Patents by Inventor Nitin K. Damle

Nitin K. Damle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEIN-POLYMER DRUG CONJUGATES
    Publication number: 20240082417
    Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
    Type: Application
    Filed: July 14, 2022
    Publication date: March 14, 2024
    Inventors: Roger A. Smith, Nitin K. Damle, Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Cheri A. Stevenson, Venu R. Gurijala
  • PROTEIN-POLYMER-DRUG CONJUGATES
    Publication number: 20230183326
    Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
    Type: Application
    Filed: July 14, 2022
    Publication date: June 15, 2023
    Inventors: Roger A. Smith, Nitin K. Damle, Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Cheri A. Stevenson, Venu R. Gurijala
  • Protein-polymer-drug conjugates
    Patent number: 11434278
    Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: September 6, 2022
    Assignee: Asana BioSciences, LLC
    Inventors: Roger A. Smith, Nitin K. Damle, Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Cheri A. Stevenson, Venu R. Gurijala
  • PROTEIN-POLYMER-DRUG CONJUGATES
    Publication number: 20190241649
    Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
    Type: Application
    Filed: April 12, 2019
    Publication date: August 8, 2019
    Inventors: Roger A. Smith, Nitin K. Damle, Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Cheri A. Stevenson, Venu R. Gurijala
  • Protein-polymer-drug conjugates
    Patent number: 10316080
    Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: June 11, 2019
    Assignee: Asana BioSciences, LLC
    Inventors: Roger A. Smith, Nitin K. Damle, Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Cheri A. Stevenson, Venu R. Gurijala
  • ANTI-5T4 ANTIBODIES AND USES THEREOF
    Publication number: 20180162937
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Application
    Filed: January 30, 2018
    Publication date: June 14, 2018
    Applicant: WYETH LLC
    Inventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Sreekumar R. KODANGATTIL
  • Anti-5T4 antibodies and uses thereof
    Patent number: 9902771
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: February 27, 2018
    Assignee: WYETH LLC
    Inventors: Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Sreekumar R. Kodangattil
  • ANTI-5T4 ANTIBODIES AND USES THEREOF
    Publication number: 20160185859
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 30, 2016
    Applicant: WYETH LLC
    Inventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Sreekumar R. KODANGATTIL
  • PROTEIN-POLYMER-DRUG CONJUGATES
    Publication number: 20150125474
    Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
    Type: Application
    Filed: October 10, 2014
    Publication date: May 7, 2015
    Inventors: Roger A. Smith, Nitin K. Damle, Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Cheri A. Stevenson, Venu R. Gurijala
  • ANTI-5T4 ANTIBODIES AND USES THEREOF
    Publication number: 20140308302
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Application
    Filed: May 29, 2014
    Publication date: October 16, 2014
    Inventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Kodangattil R. SREEKUMAR
  • Anti-5T4 antibodies and uses thereof
    Patent number: 8759495
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: June 24, 2014
    Assignee: Wyeth LLC
    Inventors: Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil R. Sreekumar
  • THERAPEUTIC COMPOSITIONS AND METHODS
    Publication number: 20120121505
    Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 17, 2012
    Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
  • ANTI-5T4 ANTIBODIES AND USES THEREOF
    Publication number: 20120064600
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Application
    Filed: August 11, 2011
    Publication date: March 15, 2012
    Applicant: WYETH LLC
    Inventors: Erwin R. BOGHAERT, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil R. Sreekumar
  • Anti-5T4 antibodies and uses thereof
    Patent number: 8044178
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: October 25, 2011
    Assignee: Wyeth LLC
    Inventors: Erwin R. Boghaert, Nitin K. Damle, Philip Ross Hamann, Kiran Khandke, Arthur Kunz, Kimberly A. Marquette, Lioudmila Tchistiakova, Davinder Gill, Kodangattil Sreekumar
  • ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS
    Publication number: 20100330089
    Abstract: The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.
    Type: Application
    Filed: June 12, 2008
    Publication date: December 30, 2010
    Applicants: Wyeth, Trubion Pharmaceuticals Inc.
    Inventors: Nitin K. Damle, Lioudmila Tchistiakova, Kyriaki Dunussi-Joannopoulos, Sandy Alexander Simon, William Brady, Laura Sue Grosmaire, Jeffrey Alan Ledbetter
  • HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES
    Publication number: 20100173382
    Abstract: Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: October 16, 2009
    Publication date: July 8, 2010
    Applicant: Wyeth
    Inventors: Erwin R. Boghaert, Nitin K. Damle, Davinder S. Gill, Kimberly A. Marquette, Lioudmila Tchistiakova, Philip Ross Hamann, Arthur Kunz
  • HUMANIZED ANTI-5T4 ANTIBODIES AND ANTI-5T4/CALICHEAMICIN CONJUGATES
    Publication number: 20100021483
    Abstract: Chimeric and humanized anti-5T4 antibodies and antibody/drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: July 1, 2009
    Publication date: January 28, 2010
    Applicant: Wyeth
    Inventors: ERWIN R. BOGHAERT, Nitin K. Damle, Davinder S. Gill, Kimberly A. Marquette, Lioudmila Tchistiakova, Philip Ross Hamann, Arthur Kunz
  • Soluble CTLA4 mutant molecules and uses thereof
    Publication number: 20090317397
    Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
    Type: Application
    Filed: June 30, 2009
    Publication date: December 24, 2009
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Philip M. Wallace
  • Therapeutic compositions and methods
    Publication number: 20090304590
    Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.
    Type: Application
    Filed: October 27, 2008
    Publication date: December 10, 2009
    Applicants: Wyeth, Trubion Pharmaceuticals, Inc.
    Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
  • Soluble CTLA4 mutant molecules
    Patent number: 7572772
    Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: August 11, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Nitin K. Damle, William Brady, Philip M. Wallace